Purchase of common stock and pre-funded warrants in the 2024 Public Offering
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Alfred Sandrock, M.D., Ph.D.
Also a director
Director, President and Chief Executive Officer
|
68 | Not stated | Not stated | $2,508,370 | |
|
Nathan Jorgensen
Chief Financial Officer; Principal Financial Officer and Principal Accounting Officer
|
Not stated | Not stated | Not stated | Not reported | |
|
Robin Swartz
President
Title from the Form 4 dated Nov 1, 2026
|
Not stated | Not stated | Not stated | $1,454,300 | |
|
Gregory Shiferman
Senior Vice President, General Counsel & Secretary
|
Not stated |
Since 2026
this year
|
Not stated | Not reported | |
|
Todd Carter, Ph.D.
Chief Scientific Officer
|
Not stated |
Since 2022
4 years
|
2016 | Not reported | |
|
Todd Alfred Carter
Chief Scientific Officer
Title from the Form 4 dated Nov 1, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Amy Quinlan
Principal Accounting Officer
Title from the Form 3 dated May 8, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchase of common stock and pre-funded warrants in the 2024 Public Offering
Purchase of common stock in the 2024 Public Offering
Purchase of common stock in the 2024 Public Offering
Cashless exercise of all outstanding pre-funded warrants resulting in issuance of 3,332,544 net shares
Separation agreement providing salary continuation for twelve months, prorated 2025 bonus, COBRA premium payments and outplacement services
Consulting agreement with hourly consulting fees, expense reimbursement and modified equity award vesting
Separation agreement providing salary continuation for twelve months, prorated 2024 bonus and COBRA premium payments
Consulting agreement with hourly consulting rate; no consulting fees paid for 2024 and modified equity award vesting
Collaboration and license agreements (2019 and 2023) for AAV gene therapy products, including cost reimbursements and collaboration revenue
Loading...